Fig. 3
68Ga-NOTA-GZP PET/CT imaging and quantitative analysis in LLC tumors. (a) Scheme for PET/CT imaging and dosing schedule of hypoxia-improved immunotherapy exploration study. Mice were treated with CmPF, PF, and saline on Day 0, followed by PD-1 inhibitor administration on Day 1 and Day 4 (n = 3). (b) Representative 68Ga-NOTA-GZP PET/CT maximal intensity projection (MIP) and transverse section images in LLC tumor models at 1 h post-radiotracer injection on Day 1 and Day 4. Tumors were indicated by white circles and arrows. (c) The quantitative analysis of tumor uptake at tumor sites of CmPF, PF and saline groups in the 68Ga-NOTA-GZP PET/CT imaging on Day 4. (d) Tumor-to-blood (T/B) ratios and (e) tumor-to-muscle (T/M) ratios of 68Ga-NOTA-GZP in LLC xenografts. T/B and T/M was calculated by drawn ROI in the images of 68Ga-NOTA-GZP images. Values are the means ± SD (n = 3). * and ** indicate P < 0.05 and P < 0.01, respectively